Compare
Lyell Immunopharma, Inc. vs Impact Biomedical Inc. vs Talphera, Inc. vs HCW Biologics Inc.
| Latest fiscal year | Lyell Immunopharma, Inc. LYEL | Impact Biomedical Inc. IBO | Talphera, Inc. TLPH | HCW Biologics Inc. HCWB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $36.0K | $32.0K | $28.0K | $54.2K |
| Revenue growth (YoY) | -41.0% | n/a | n/a | -97.9% |
| Gross margin | n/a | n/m (computed) | n/a | 20.0% |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$274.45M | -$11.84M | -$14.29M | -$7.96M |
| EPS (Diluted) | -$16.06 | -$0.38 | n/a | -$10.63 |
| Operating cash flow | -$150.02M | -$1.89M | -$11.36M | -$13.39M |
| Free cash flow | -$150.80M | n/a | n/a | -$13.39M |
| Cash & equivalents | $60.18M | $3.0K | $5.89M | $1.95M |
| Total assets | $340.05M | $17.41M | $29.72M | $24.52M |
| Total liabilities | $91.85M | $1.85M | $12.68M | $21.76M |
| Shareholders' equity | $248.20M | $12.61M | $17.04M | $2.76M |
| Return on year-end equity | -110.6% | -93.9% | -83.9% | -287.9% |
| Shares outstanding | 21.25M | 104.62M | 49.33M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Lyell Immunopharma, Inc. | Impact Biomedical Inc. | Talphera, Inc. | HCW Biologics Inc. |
|---|---|---|---|---|
| Latest | $36.0K Ended 2025-12-31 | $32.0K Ended 2025-12-31 | $28.0K Ended 2025-12-31 | $54.2K Ended 2025-12-31 |
| 1 year earlier | $61.0K Ended 2024-12-31 | n/a | $0 Ended 2024-12-31 | $2.57M Ended 2024-12-31 |
| 2 years earlier | $130.0K Ended 2023-12-31 | n/a | $651.0K Ended 2023-12-31 | $2.84M Ended 2023-12-31 |
| 3 years earlier | $84.68M Ended 2022-12-31 | $50.0K Ended 2022-12-31 | $0 Ended 2022-12-31 | $6.72M Ended 2022-12-31 |
| 4 years earlier | $10.65M Ended 2021-12-31 | n/a | $2.82M Ended 2021-12-31 | $0 Ended 2021-12-31 |